GDF15 and urothelial carcinoma: The latest clinical studies have confirmed that GDF15 inhibits T cell function and migration, and that the combination of GDF15‐neutralising antibody visugroumab significantly enhances the efficacy of the PD‐1 antibody Nivolumab in non‐squamous non‐small cell lung cancer and urothelial carcinoma.74